Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration (P52901)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Palomid 529 is a dual TORC1/2 inhibitor of the PI3K/Akt/mTOR pathway having broad activity in angiogenesis and cellular proliferation. Palomid 529 will be examined to determine if the safety, tolerability and pharmacokinetic profile of single ascending doses when administered intravitreally or subconjunctivally.
A Phase I Open-Label Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single Intravitreal and Subconjunctival Doses of Palomid 529 in Patients With Advanced Neovascular Age-Related Macular Degeneration (AMD)
Study Start Date :
Actual Primary Completion Date :
Actual Study Completion Date :
Resource links provided by the National Library of Medicine
Efficacy-Mean change in visual acuity by ETDRS testing-Decreased leakage and/or size on FA, decreased retinal thickness in OCT-Decreased fibrosis if detectable based on fundus examination, photography, angiography and OCT [ Time Frame: 43 days ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
50 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Best corrected visual acuity in the study eye between 20/100 and 20/800 (between 53 and 4 ETDRS letters read), and better or equal to 20/200 (minimum of 34 letters read) in the fellow eye.
Subfoveal choroidal neovascularization (CNV) due to AMD
Total area of the lesion (including blood, neovascularization and scar/atrophy) must be < 12 DA.
Only 1 eye will be treated in the study. If both eyes are eligible, the investigator will select the eye with the most active CNV
Clear ocular media and adequate pupillary dilatation to permit good stereo fundus photography for screening
Intraocular pressure of 21 mm Hg or less
Retinal thickness ≥ 250 μm by OCT, with presence of intraretinal or subretinal fluid
Any retinovascular disease or retinal degeneration other than AMD
Serous pigment epithelial detachment without the presence of neovascularization
Previous posterior vitrectomy or retinal surgery
Any periocular infection in the past 4 weeks
Concomitant therapy with anti-VEGF therapies, e.g. Avastin, Lucentis or Macugen, or previous use of these agents within 60 days of screening
Concomitant therapy with intravenous or intravitreous corticosteroids or use within 90 days of screening
Significant media opacities, including cataract, which might interfere with visual acuity, assessment of toxicity, or fundus photography
Cataract surgery in the study eye within 3 months of screening
Intraocular surgery in the study eye within 3 months of screening
Presence of ocular infection in the study eye
Presence of severe myopia (-8 diopters or greater) in the study eye